Tirzepatide side chain Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH
2 Inquiries
2460751-66-8
Pharmaceutical Grade
95%
Dalian, Beijing or Shanghai
HANDOM CHEM
1g; 5g; 10g; 100g; 500g; 1kg; 2kg; 5kg
2023-09-30
Semaglutide,Tirzepatide,HCG,Retatrutide,Cagrilintide,Medetomidine
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH
Other Name:Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH;Fmoc Lys[AEEA-AEEA-Y-Glu(OtBu)-C20-otBu]-OH;Fmoc-Lys(AEEA-AEEA-γ-Glu(OtBu)-Eic-OtBu)-OH;Fmoc-Lys[tBuO-Ara-Glu(AEEA-AEEA)-OtBu]-OH;(25R,52S)-52-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-25-(tert-butoxycarbonyl)-2,2-dimethyl-4,23,28,37,46-pentaoxo-3,32,35,41,44-pentaoxa-24,29,38,47-tetraazatripentacontan-53-oic acid;Fmoc-Lys(tBuO-ICO-Glu(AEEA-AEEA)-OtBu)-OH;Fmoc-Lys Tirzepatide side chain;Semaglutide Fatty Acid Side Chain Intermediate
CAS No.:2460751-66-8
Molecular Formula:C66H105N5O16
InChIKeys:YWLOWAZATOAHDO-VWLOGKTGNA-N
Molecular Weight:1224.59
Categories:
Characteristics-
Density:
1.121±0.06 g/cm3(Predicted)
Boiling Point:1225.0±65.0 °C(Predicted)
PKA:3.87±0.21(Predicted)
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Semaglutide,Tirzepatide,HCG,Retatrutide,Cagrilintide,Medetomidine
-
Location:
RM702, Building 21, Liuhe Road, Ganjingzi Dist, Dalian, Liaoning, China
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2020
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
India
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH
1.023 KG Mar 5, 2026
Germany
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH 99.0% Powder ECHEMI
1 G Nov 7, 2023 Post an enquiry for this product
